Entera Bio

Entera Bio Shares Outstanding

The The number of shares of Entera Bio (ENTX) as of Nov 22, 2026 is 37.65 M. In the previous year, The number of shares was 37.65 M — a change of 0.00% (lower).

Shares Outstanding

37.65 M

YoY

0.00%

Last updated:

In 2025, Entera Bio had 37.65 M outstanding stocks, a 0.00% change from the 37.65 M stocks in the previous year.

The Entera Bio Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2020
37.65 M USD
Jan 1, 2021
37.65 M USD
Jan 1, 2022
37.65 M USD
Jan 1, 2023
37.65 M USD
Jan 1, 2024
37.65 M USD
Jan 1, 2025
37.65 M USD
Jan 1, 2026 (e)
46.19 USD
Jan 1, 2027 (e)
46.19 USD
The Entera Bio Shares Outstanding history
YEARShares OutstandingYoY
est46.190.00%
est46.19-100.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M0.00%
37.65 M—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Number of shares

Entera Bio shares outstanding

The number of shares of Entera Bio was 46.19 M in 2025. This indicates how many shares Entera Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
18.33 M Stocks
Jan 1, 2021
28.68 M Stocks
Jan 1, 2022
28.81 M Stocks
Jan 1, 2023
29.70 M Stocks
Jan 1, 2024
37.65 M Stocks
Jan 1, 2025
46.19 M Stocks
Jan 1, 2026 (e)
46.19 M Stocks
Jan 1, 2027 (e)
46.19 M Stocks

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Entera Bio's Shares Outstanding

Entera Bio's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Entera Bio’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Entera Bio’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Entera Bio’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Entera Bio stock

The number of shares of Entera Bio is 37.65 M in 2025.

The number of shares of Entera Bio changed from 37.65 M to 37.65 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Entera Bio since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Entera Bio

All Key Metrics — Entera Bio